Glucocerebrosidase Gene Therapy Induces Alpha-Synuclein Clearance and Neuroprotection of Midbrain Dopaminergic Neurons in Mice and Macaques
Mutations in the GBA1 gene coding for glucocerebrosidase (GCase) are the main genetic risk factor for Parkinson’s disease (PD). Indeed, identifying reduced GCase activity as a common feature underlying the typical neuropathological signatures of PD—even when considering idiopathic forms of PD—has re...
Main Authors: | Diego Sucunza, Alberto J. Rico, Elvira Roda, María Collantes, Gloria González-Aseguinolaza, Ana I. Rodríguez-Pérez, Iván Peñuelas, Alfonso Vázquez, José L. Labandeira-García, Vania Broccoli, José L. Lanciego |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-05-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/1422-0067/22/9/4825 |
Similar Items
-
Glucocerebrosidase Defects as a Major Risk Factor for Parkinson’s Disease
by: Micol Avenali, et al.
Published: (2020-04-01) -
Glucocerebrosidase gene therapy prevents α-synucleinopathy of midbrain dopamine neurons
by: Emily M. Rocha, et al.
Published: (2015-10-01) -
Glucocerebrosidase Mutations and Synucleinopathies. Potential Role of Sterylglucosides and Relevance of Studying Both GBA1 and GBA2 Genes
by: Rafael Franco, et al.
Published: (2018-06-01) -
Association Between Glucocerebrosidase Mutations and Parkinson's Disease in Ireland
by: Diana A. Olszewska, et al.
Published: (2020-06-01) -
Silencing of Glucocerebrosidase Gene in Drosophila Enhances the Aggregation of Parkinson's Disease Associated α-Synuclein Mutant A53T and Affects Locomotor Activity
by: Salema B. Abul Khair, et al.
Published: (2018-02-01)